|Bid||0.00 x 800|
|Ask||344.24 x 900|
|Day's range||336.84 - 343.00|
|52-week range||168.65 - 344.81|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||67.33|
|Earnings date||30 Jul 2020 - 03 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||300.60|
IDEXX's (IDXX) human health business, OPTI Medical Systems' newly-developed PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR gains market acceptance.
HOLX vs. IDXX: Which Stock Is the Better Value Option?
You could ask 100 different analysts what they think about buying and selling stocks during COVID-19, and you might just get 100 different opinions. If you have $1,000 to invest, now could be a great opportunity to start a new position, and billion-dollar hedge fund managers have been scooping up shares of IDEXX Laboratories (NASDAQ: IDXX), Goodyear Tire (NASDAQ: GT) and Starbucks (NASDAQ: SBUX). You may not recognize IDEXX Laboratories, but if you're a pet owner there's a chance you've crossed paths with its products or services already.
WESTBROOK, Maine , April 20, 2020 /CNW/ -- IDEXX Laboratories, Inc. (IDXX), a global leader in veterinary diagnostics and software, today announced the availability of the IDEXX SARS-CoV-2 (COVID-19) RealPCR™ Test for pets. IDEXX is launching the test in response to customer demand and growing evidence that in rare cases pets living with COVID-19 positive humans can be at risk for SARS-CoV-2 infection. The test will be available to veterinarians in North America this week and will continue to roll out across most of the world in the coming weeks, enabled by IDEXX Reference Laboratories, the company's worldwide network of more than 80 laboratories.
Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.
Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Idexx (IDXX) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Investing.com - IDEXX Labs (NASDAQ:IDXX) reported on Friday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.